dc.contributor.author | Uribe, Kepa B. | |
dc.contributor.author | Benito Vicente, Asier | |
dc.contributor.author | Martín Plágaro, César Augusto | |
dc.contributor.author | Blanco Vaca, Francisco | |
dc.contributor.author | Rotllan, Noemi | |
dc.date.accessioned | 2021-05-27T08:24:59Z | |
dc.date.available | 2021-05-27T08:24:59Z | |
dc.date.issued | 2021-03-19 | |
dc.identifier.citation | Biomaterials Science 9 : 3185-3208 (2021) | es_ES |
dc.identifier.issn | 2047-4830 | |
dc.identifier.issn | 2047-4849 | |
dc.identifier.uri | http://hdl.handle.net/10810/51636 | |
dc.description.abstract | High-density lipoproteins (HDL) are key players in cholesterol metabolism homeostasis since they are responsible for transporting excess cholesterol from peripheral tissues to the liver. Imbalance in this process, due to either excessive accumulation or impaired clearance, results in net cholesterol accumulation and increases the risk of cardiovascular disease (CVD). Therefore, significant effort has been focused on the development of therapeutic tools capable of either directly or indirectly enhancing HDL-guided reverse cholesterol transport (RCT). More recently, in light of the emergence of precision nanomedicine, there has been renewed research interest in attempting to take advantage of the development of advanced recombinant HDL (rHDL) for both therapeutic and diagnostic purposes. In this review, we provide an update on the different approaches that have been developed using rHDL, focusing on the rHDL production methodology and rHDL applications in theranostics. We also compile a series of examples highlighting potential future perspectives in the field. | es_ES |
dc.description.sponsorship | This review was funded by Ministerio de Ciencia, Innovacion y Universidades (PID2019-104367RB-100), as well as the Subprograma Ramon y Cajal (RYC-201722879) to N.R. and PI18/0164 to F.B.-V., FEDER "Una manera de hacer Europa". CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM) is a project of Instituto de Salud Carlos III. Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is accredited by the Generalitat de Catalunya as Centre de Recerca de Catalunya (CERCA). This work was also supported by the Basque Government (Grupos Consolidados IT-1264-19) to C.M. and A.B.-V. was supported by Programa de especializacion de Personal Investigador Doctor en la UPV/EHU (2019) 2019-2020. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Royal Society Of Chemistry | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2019-104367RB-100 | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/RYC-2017-22879 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | lipoproteins | es_ES |
dc.title | (r)HDL in Theranostics: How Do We Apply HDL's Biology for Precision Medicine in Atherosclerosis Management? | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC 3.0) | es_ES |
dc.rights.holder | Atribución-NoComercial 3.0 España | * |
dc.relation.publisherversion | https://pubs-rsc-org.ehu.idm.oclc.org/en/content/articlelanding/2021/bm/d0bm01838d#!divAbstract | es_ES |
dc.identifier.doi | 10.1039/d0bm01838d | |
dc.departamentoes | Bioquímica y biología molecular | es_ES |
dc.departamentoeu | Biokimika eta biologia molekularra | es_ES |